Alzheimer's dementia: Budget impact and cost-utility analysis of a combination treatment with a cholinesterase inhibitor and memantine in Switzerland

Swiss Medical Weekly

Volumn 142, Issue , 2012, Pages

  Pfeil, Alena M ^a   Kressig, Reto W ^b   Szucs, Thomas D ^a  

^a UNIVERSITY OF BASEL   (Switzerland)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Alzheimer's dementia; Budget impact analysis; Cholinesterase inhibitor; Cost; Cost effectiveness analysis; Cost utility analysis; Dementia; Economic evaluation; Memantine

Indexed keywords

CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; MEMANTINE; RIVASTIGMINE; DOPAMINE RECEPTOR STIMULATING AGENT;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; BUDGET; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; FEMALE; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; POPULATION; PREVALENCE; QUALITY ADJUSTED LIFE YEAR; REIMBURSEMENT; SWITZERLAND; AGE; COST BENEFIT ANALYSIS; DRUG COMBINATION; ECONOMICS; FEE; HEALTH SERVICE; HOME FOR THE AGED; MIDDLE AGED; NURSING HOME; PROBABILITY; SEVERITY OF ILLNESS INDEX; SEX DIFFERENCE; STATISTICAL MODEL; STATISTICS; UTILIZATION REVIEW; VERY ELDERLY;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; COST-BENEFIT ANALYSIS; DOPAMINE AGENTS; DRUG THERAPY, COMBINATION; FEES, PHARMACEUTICAL; HEALTH SERVICES; HOMES FOR THE AGED; HUMANS; MARKOV CHAINS; MEMANTINE; MIDDLE AGED; MODELS, ECONOMETRIC; NURSING HOMES; PREVALENCE; QUALITY-ADJUSTED LIFE YEARS; SEVERITY OF ILLNESS INDEX; SEX FACTORS; SWITZERLAND;

EID: 84870403436     PISSN: 14247860     EISSN: None     Source Type: Journal    
DOI: 10.4414/smw.2012.13676     Document Type: Article

References (42)

1. Jalbert JJ, Daiello LA, Lapane KL. Dementia of the Alzheimer type. Epidemiol Rev. 2008;30:15-34.
2. Harvey HJ, Rossor MN, Skelton-Robinson M, Garralda E. Young onset dementia: epidemiology, clinical symptoms, family burden, support, and outcome. Dementia Research Group. Imperial College of Science, Technology and Medicine. London: 1998.
3. Hofman A, Rocca WA, Brayne C, Breteler MMB, Clarke M, Cooper B, et al. The prevalence of dementia in Europe: a collaborative study of 1980-1990 findings. Int J Epidemiol. 1991;20(3):736.
4. Wimo A and Prince M. World Alzheimer Report 2010: the global economic impact of dementia. Alzheimer's Disease International. 2010.
5. Volz A, Monsch AU, Zahno A, Wettstein A, Stähelin HB, Grünig R. Was kostete die Schweiz die Alzheimer-Krankheit 1998? Eine präliminä re Analyse. Praxis. 2000;89:803-11.
6. Sadik K and Wilcock G. The increasing burden of Alzheimer disease. Alzheimer Dis Assoc Disord. 2003;17:S75-S79. (Pubitemid 37205719)
7. Wimo A, Winblad B, Jönsson L. The worldwide societal costs of dementia: Estimates for 2009. Alzheimer's & Dementia. 2010;6:98-103.
8. th International Conference on Alzheimer's & Parkinson's Diseases, 2011
9. Atri A, Shaughnessy LW, Locascio JJ, and Growdon JH. Long-term course and effectiveness of combination treatment in Alzheimer disease. Alzheimer Dis Assoc Disord. 2008;22(3):209-21.
10. Lopez OL, Becker JT, Wahed AS, Saxton J, Sweet RA, Wolk DA, et al. Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease. J Neurol Neurosurg Psychiatry. 2009;80:600-7.
11. Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil. JAMA. 2004;291(3):317-24. (Pubitemid 38101604)
12. Howard R, McShane R, Lindesay J, Ritchie C, Baldwin A, Barber R, et al. Donepezil and memantine for moderate-to-severe Alzheimer's disease. N Engl J Med. 2012;366:893-903.
13. Farrimond LE, Roberts E, McShane R. Memantine and cholinesterase inhibitor combination therapy for Alzheimer's disease: a systematic review. BMJ Open. 2012;2(3):e000917.
14. Kraft E, Marti M, Werner S, Sommer H. Cost of dementia in Switzerland. Swiss Med Wkly. 2010;140:w13093
15. Rive B, Aarsland D, Grishchenko M, Cochran J, Lamure M, Toumi M. Cost-effectiveness of memantine in moderate and severe Alzheimer's disease in Norway. Int J Geriatr Psychiatry. 2011. Epub ahead of print. doi: 10.1002/gps.2755.
16. Hoogveldt B, Rive B, Severens J, Maman K, Guilhaume C. Cost-effectiveness of memantine for moderate-to-severe Alzheimer's disease in the Netherlands. Neuropsychiatr Dis Treat. 2011;7:313-7.
17. Rive B, Grishchenko M, Guilhaume-Goulant C, Katona C, Livingston G, Lamure M, et al. Cost effectiveness of memantine in Alzheimer's disease in the UK. J Med Econ. 2010;13(2):371-80.
18. Gagnon M, Rive B, Hux M, Guilhaume C. Cost-effectiveness of memantine compared with standard care in moderate-to-severe Alzheimer disease in Canada. Can J Psychiatry. 2007;52(8):519-26. (Pubitemid 47403186)
19. François C, Sintonen H, Sulkava R, Rive B. Cost-effectiveness of memantine in moderately severe to severe Alzheimer's disease: A Markov model in Finland. Clin Drug Investig. 2004;24(7):373-84. (Pubitemid 38951789)
20. Antonanzas F, Rive B, Badenas JM, Gomez-Lus S, Guilhaume C. Cost-effectiveness of memantine in community-based Alzheimer's disease patients: an adaption in Spain. Eur J Health Econ. 2006;7:137-44. (Pubitemid 44562258)
21. Jones RW, McCrone P, Guilhaume C. Cost-effectiveness of memantine in Alzheimer's disease: an analysis based on a probabilistic Markov model from a UK perspective. Drugs Aging. 2004;21(9):607-20. (Pubitemid 39070995)
22. Jönsson L. Cost-effectiveness of memantine for moderate to severe Alzheimer's disease in Sweden. Am J Geriatr Pharmacother. 2005; 3(2):77-86. (Pubitemid 41200509)
23. Lachaine J, Beauchemin C, Legault M, Bineau S. Economic evaluation of the impact of memantine on time to nursing home admission in the treatment of Alzheimer disease. Can J Psychiatry. 2011;56(10):596-604.
24. th ISPOR Annual European Congress, 2010.
25. ECOPLAN. Kosten der Demenz in der Schweiz - Schlussbericht. Studie im Auftrag der Schweizerischen Alzheimervereinigung. Bern: 2010.
26. Bundesamt für Statistik. Ständige Wohnbevölkerung 2011. Available from: http://www.bfs.admin.ch/bfs/portal/de/index/themen/01/02/blank/ key/alter/nach-geschlecht.html Access at: 20 October 2011
27. Bundesamt für Statistik. Zukünftige Bevö lkerungsentwicklung der Schweiz in den Jahren 2012-2016. Available from: http://www.bfs.admin.ch/bfs/portal/de/index/themen/01/03.html Access at: 20 October 2011
28. Schweizerische Alzheimervereinigung. Zahlen zur Demenz - Kosten der Demenz in der Schweiz: Update 2009. Available from: http://www.alz.ch/d/data/ data-883.pdf Access at: 3 October 2011.
29. CSS Gruppe. FaktenBlatt Gesundheitspolitik - Fragen und Antworten zur Kosten- und Prämienentwicklung im Gesundheitswesen. Available from: https://www.css.ch/media/de/ documents/ueber-uns/the-men-im-fokus/faktenblatt-d- kostenentwicklung.pdf Access at: 17 November 2011
30. Schweizerische Alzheimervereinigung. Demenz und Gesellschaft - Fakten zur Demenz. Available from: http://www.alz.ch/d/data/data-781.pdf Access at: 20 October 2011
31. IMS Health. Antidementia drugs in Europe and USA - percentage of population treated with antidementia drugs from 2005-2009 [Graphic].
32. Tifratene K, Le Duff F, Pradier C, Quetel R, Robert P. Usage des medicaments anti-Alzheimer en France: une analyse des pratiques à partir de la Banque Nationale de données Alzheimer (BNA). La Revue de gériatrie. 2011;36(8):557-65.
33. Haute Autorité de Santé - Médicaments: EBIXA Available from: http://www.has-sante.fr/portail/jcms/c-1117850/ebixa?xtmc= Ebixa&xtcr=1 Access at: 6 December 2011
34. Ward A, Caro JJ, Getsios D, Ishak K, O'Brien J, Bullock R; AHEAD Study Group. Assessment of health economics in Alzheimer's disease (AHEAD): treatment with galantamine in the UK. Int J Geriatr Psychiatry. 2003;18(8):740-7. (Pubitemid 37009757)
35. Neumann PJ, Kuntz KM, Leon J, Araki SS, Hermann RC, Hsu MA, et al. Health utilities in Alzheimer's disease: a cross-sectional study of patients and caregivers. Med Care. 1999;37(1):27-32.
36. Helmer C, Joly P, Commenges D, Dartigues J-F. Mortality with dementia: results from a French prospective community-based cohort. Am J Epidemiol 2001;154:642-8. (Pubitemid 32888782)
37. Bundesamt für Statistik. Apotheken/SD-Ärzte Index Schweiz. Available from: http://www.obsan.admin.ch/bfs/obsan/de/index/04/04/blank/blank/ sdaindex/01.html Access at: 17 November 2011
38. WHO. Cost-effectiveness thresholds. Available from: http://www.who.int/ choice/costs /CER-thresholds/en/index.html Access at: 6 December 2011
39. NICE. Measuring effectiveness and cost-effectiveness: the QALY. Available from: http://www.nice.org.uk/newsroom/features/ measuringeffectivenessandcosteffectivenesstheqaly.jsp Access at: 6 December 2011
40. PharmaWiki - Medikamente und Gesundheit: Donepezil. Available from: http://www.pharmawiki.ch/wiki/index.php?wiki=Donepezil Access at: 30 April 2012.
41. Mein Gesundheitszentrum - Alzheimer: Aricept. Available from: http://www.meingesundheitszentrum.de/aricept-alzheimer/ Access at: 30 April 2012.
42. Arzneimittel-Kompendium der Schweiz® - Donepezil. Available from: www.kompendium.ch Access at: 7 August 2012.